Wu L.-W.JIA-HORNG KAO2021-09-042021-09-0420110929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855835734&doi=10.1016%2fj.jfma.2011.11.017&partnerID=40&md5=07bdc3e5b50843fd0a0644aea877e330https://scholars.lib.ntu.edu.tw/handle/123456789/582049[SDGs]SDG3antivirus agent; tuberculostatic agent; blood sampling; clinical evaluation; comorbidity; disease association; disease course; disease severity; echography; hepatitis; hepatitis B; Hepatitis B virus; Hepatitis C virus; human; letter; liver biopsy; liver cirrhosis; liver failure; liver function test; screening; tuberculosis; virus hepatitis; virus load; Antitubercular Agents; Female; Hepatitis; Humans; Male; Tuberculosisletter10.1016/j.jfma.2011.11.017222488412-s2.0-84855835734